Developmental stage biopharmaceutical company specializing on merging traditional therapeutics and psychedelic research Silo Pharma Inc. (OTCQB: SILO) has joined forces with University California San Francisco to study the properties of psilocybin as an anti-inflammatory agent in Parkinson’s disease, Bipolar disorder and chronic back pains.
Silo Pharma announced having entered into a Scientific Research Agreement (SRA) with the University of California San Francisco (UCSF). This agreement will leverage other four clinical trials being planned by the University also to establish the anti-inflammatory effects of psilocybin in patients with various conditions.
This announcement was made by the chief executive officer of Silo Pharma Eric Weisblum, who said this agreement will help both parties to have a better understanding on anti-inflammatory effects of psilocybin.
“Inflammation is a common mechanism across numerous physical diseases. Inflammation has specifically been implicated in the pathophysiology of Parkinson’s Disease, chronic pain, and bipolar disorder. Psilocybin and related compounds have shown strong anti-inflammatory effects in non-human animals, raising the possibility that reducing inflammation is a possible mechanism underlying psilocybin’s positive treatment effects in multiple disorders. A better understanding of the anti-inflammatory effects of psilocybin has potential to allow for optimization and personalization of psilocybin treatment,” said the CEO.
